Ocuphire Pharma Inc
NASDAQ:OCUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Trex Company Inc
NYSE:TREX
|
US |
Ocuphire Pharma Inc
Net Income
Ocuphire Pharma Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ocuphire Pharma Inc
NASDAQ:OCUP
|
Net Income
-$14.1m
|
CAGR 3-Years
41%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income
$26.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Ocuphire Pharma Inc
Glance View
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.
See Also
What is Ocuphire Pharma Inc's Net Income?
Net Income
-14.1m
USD
Based on the financial report for Jun 30, 2024, Ocuphire Pharma Inc's Net Income amounts to -14.1m USD.
What is Ocuphire Pharma Inc's Net Income growth rate?
Net Income CAGR 10Y
3%
The average annual Net Income growth rates for Ocuphire Pharma Inc have been 41% over the past three years , -1% over the past five years , and 3% over the past ten years .
